Immuneering (IMRX) Q3 2026 earnings summary

Executive summary

• Q3 net loss widened to $24.2M from $15.0M YoY as late-stage atebimetinib development, particularly MAPKeeper 301, drove higher R&D spending.

• Cash, cash equivalents and marketable securities totaled $166.1M at Sept. 30, 2026; expected runway was revised from 2029 to Q4 2028.

• Atebimetinib is in Phase 3 first-line pancreatic cancer and Phase 1/2a advanced solid tumor trials; no product candidates are approved for sale.

• Phase 2 atebimetinib plus mGnP follow-up was extended as patients lived longer than projected; updated data for 55 patients is expected in 1H 2027.

Financial highlights

• Q3 2026 operating expenses and operating loss were $25.8M vs. $15.4M YoY; net loss was $24.2M vs. $15.0M.

• 9M 2026 operating expenses and operating loss were $60.1M vs. $45.6M YoY; net loss was $54.9M vs. $44.4M.

• Q3 R&D rose 90.7% to $20.7M from $10.9M, primarily due to higher lead-program clinical costs, including $8.5M in higher MAPKeeper 301 costs.

• Q3 G&A increased 12.3% to $5.1M from $4.5M; 9M G&A rose 15.1% to $14.7M, mainly from employee-related and stock-based compensation costs.

• Q3 basic and diluted loss per share was $0.37 vs. $0.38; 9M loss per share was $0.85 vs. $1.20.

Outlook and guidance

• Existing liquidity is expected to fund operations into Q4 2028, versus prior guidance into 2029; the estimate may prove incorrect and additional capital will be needed thereafter.

• Runway revision reflects extended Phase 1/2a activity, larger and faster MAPKeeper 301 enrollment, and commercial-readiness costs; R&D and G&A expenses are expected to increase.

• MAPKeeper 301 enrollment target rose from 510 to 570 patients and is ahead of schedule; topline data remain planned for mid-2028, with potential acceleration.

• Updated Phase 2 atebimetinib plus mGnP data for N=55 is expected in 1H 2027; the extended follow-up reflects longer-than-projected survival.

• First patient dosing in the atebimetinib plus cemiplimab (Libtayo) NSCLC trial and additional anti-PD-1 preclinical data are expected in Q4 2026; next-program IND-enabling work is planned for mid-2027.